InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,174.00
(
1.14%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.58
(
0.46%
)
Bitcoin
61,924.51
(
0.20%
)
Post# of 252358
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

kamehameha

Send PM Follow Ignore
Followers 4
Posts 134
Boards Moderated 0
Alias Born 05/16/2011

kamehameha

Re: genisi post# 131278

Thursday, 11/17/2011 8:26:59 AM

Thursday, November 17, 2011 8:26:59 AM

Post# of 252358

he NEUTRINO trial will enroll all genotypes who can not take interferon, including (and probably many) GT1 patients. The GT2/3 group is a sweet-spot for VRUS and based on data from ELECTRON trial, there's a very good chance that PSI-7977/RBV can cure these patients in 12 weeks.



so the label will be restricted to:
patients with GT2/3 and
patients with GT 1 who can not tolerate INF?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up